Impressive AI-aided RT breast cancer flow presented at #EBCC13 by #SofiaRivera. Challenge accepted!

#Iridiumnetwork represented at #EBCC13. With the best mentor #PhilipPoortmans 💪

📣Twitter takeover,tomorrow at 11:45 CET with Pierre Montay-Gruel 💙💛! 📍Follow us online and share your questions. Pierre Montay-Gruel 💙💛 will be answering #FRPT2022 #FLASHradiotherapy

PRIME II trial long-term results on NEJM - Outstanding results reinforcing the positive impact of postoperative RT on local recurrence regardless of age (9.5% vs 0.9% 10 years). I suggest reading this brilliant commentary by jennifer bellon and Alice Ho nejm.org/doi/full/10.10…

Magnificent overview on when and how to use a nodal boost performed by Wendy Woodward MDPhD Wendy Woodward #ESTRO23 OncoAlert #OncoAlert #radonc #breastcancer

lack of RNI benefit in low genomic score disease irrespective of whether they got chemo or not #bcsm ⁦Andrew Keller⁩ ⁦Chirag Shah⁩ ⁦Erin Gillespie, MD MPH⁩ ⁦Icro Meattini⁩ #bcsm jamanetwork.com/journals/jamao…

Happy to have contributed to this excellent review led by Melanie Machiels focused on using #TILs and genomic #biomarkers to individualize #radiotherapy in #breastcancer. thebreastonline.com/article/S0960-…

Has the time come to individualize #radiotherapy using #TILs and genomic #biomarkers?

The past is a place to learn from, not to live in 🧐 Onwards with #genomicclassifiers for individualization of #Radiotherapy

Presented at #ESMO23 data from the #Keynote756 trial showing an increased pCR rate with the addition of #pembrolizumab to neoadjuvant chemotherapy in patients with high-risk hormone receptor-positive HER2-negative #BreastCancer ESMO - Eur. Oncology OncoAlert #bcsm

Check out Dr. Paolo Tarantino Paolo Tarantino Dana-Farber’s Breast Oncology Center discussing top 5 takeaways from #SABCS23 including KATHERINE & INAVO120 #bcsm #HER2 #TNBC #BreastCancer full📽️on #VuMedi 👇 bit.ly/TOP5SABCS23

Elective node irradiation including IMN for all high-risk #breastcancer patients from now on!

Proficiat Joost Verhoeff!

Thanks to @komop_tgkanker and all the people supporting it, GZA Ziekenhuizen and the Iridium Network will be able to conduct 2 new trials: PRADA (Melanie Machiels) and OligoRare (me and Matthias Guckenberger with EORTC), trying to improve outcomes for cancer patients!

📌Does Postmastectomy Radiotherapy in 'Intermediate-Risk' Breast Cancer Impact Overall Survival? 👉🏻10-Year Results of the BIG 2-04 MRC SUPREMO Randomized Trial: On Behalf of the SUPREMO Trial Investigators by Prof Ian Kunkler #SABCS24 #day3 OncoAlert #OncoAlertAF

The interim-analysis of the groundbreaking EUROPA trial demonstrates what we all have been thinking: ⁃Much less AE’s in the RT arm ⁃Better HRQoL preservation in the RT arm Time for a paradigm shift! Congratulations Icro Meattini #SABCS24

Very honoured to present the interim-analysis of our ULTIMO trial at #SABCS24

🚨Highlights from #SABCS2024! Prof Dr Melanie Machiels explores breakthroughs from the Rapid Fire Session 2: - Axillary management: Alliance 11-202 findings - Micrometastases & DFS: German Breast Group analysis - Faster radiotherapy boosts: ULTIMATE trial outcomes - TILs in ER-negative